Corrigendum to “Cannabinoid Receptor Agonists Reduce the Short-Term Mitochondrial Dysfunction and Oxidative Stress Linked to Excitotoxicity in the Rat Brain” (Neuroscience (2015) 285 (97–106), (S0306452214009737) (10.1016/j.neuroscience.2014.11.016));Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain

Neuroscience

Volumn 285, Issue , 2015, Pages 97-106

  Rangel Lopez E ^a   Colin Gonzalez A L ^a   Paz Loyola, A L ^a   Pinzon E ^b   Torres, I ^b   Serratos, I N ^c   Castellanos, P ^c   Wajner, M ^d   Souza, D O ^d   Santamaria A ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c DEPARTAMENTO DE QUÍMICA   (Mexico)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cannabinoid receptor agonists; Endocannabinoid system; Excitotoxicity; Mitochondrial dysfunction; Neuroprotection; Oxidative stress

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; LACTATE DEHYDROGENASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURON SPECIFIC NUCLEAR PROTEIN; QUINOLINIC ACID; REACTIVE OXYGEN METABOLITE; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; AMIDE; AMINO ACID RECEPTOR AFFECTING AGENT; ARACHIDONIC ACID DERIVATIVE; BENZOXAZINE DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLOHEXANOL DERIVATIVE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL CULTURE; BRAIN MITOCHONDRION; CELL COUNT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; EMBRYO; ENZYME ANALYSIS; EXCITOTOXICITY; IMMUNOFLUORESCENCE; IN VITRO STUDY; LIPID PEROXIDATION; MALE; MTT ASSAY; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; RAT; STRIATE CORTEX; SYNAPTOSOME; ANIMAL; BRAIN; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; MITOCHONDRION; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ARACHIDONIC ACIDS; BENZOXAZINES; BRAIN; CANNABINOID RECEPTOR AGONISTS; CELL SURVIVAL; CELLS, CULTURED; CYCLOHEXANOLS; ENDOCANNABINOIDS; EXCITATORY AMINO ACID AGENTS; LIPID PEROXIDATION; MALE; MITOCHONDRIA; MORPHOLINES; NAPHTHALENES; NEURONS; OXIDATIVE STRESS; POLYUNSATURATED ALKAMIDES; QUINOLINIC ACID; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTORS, CANNABINOID; SYNAPTOSOMES;

EID: 84949116595     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2018.11.001     Document Type: Erratum

References (40)

1. Ashton J.C., Friberg D., Darlington C.L., Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 2006, 396:113-116.
2. Bénard G., Massa F., Puente N., Lourenço J., Bellocchio L., Soria-Gómez E., Matias I., Delamarre A., Metna-Laurent M., Cannich A., Hebert-Chatelain E., Mulle C., Ortega-Gutiérrez S., Martín-Fontecha M., Klugmann M., Guggenhuber S., Lutz B., Gertsch J., Chaouloff F., López-Rodríguez M.L., Grandes P., Rossigno R., Marsicano G. Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat Neurosci 2012, 15:558-564.
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
4. Braidy N., Grant R., Adams S., Brew B.J., Guillemin G.J. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 2009, 16:77-86.
5. Braidy N., Grant R., Adams S., Guillemin G.J. Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J 2010, 277:368-382.
6. Casteels C., Martinez E., Bormans G., Camon L., de Vera N., Baekelandt V., Planas A.M., Laere K.V. Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism. Eur J Nucl Med Mol Imaging 2010, 37:2354-2363.
7. Chiarlone A., Bellocchio L., Blázquez C., Resel E., Soria-Gómez E., Cannich A., Ferrero J.J., Sagredo O., Benito C., Romero J., Sánchez-Prieto J., Lutz B., Fernández-Ruiz J., Galve-Roperh I., Guzmán M. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci 2014, 111:8257-8262.
8. Citraro R., Russo E., Ngomba R.T., Nicoletti F., Scicchitano F., Whalley B.J., Calignano A., De Sarro G. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. Epilepsy Res 2013, 106:74-82.
9. De March Z., Zuccato C., Giampá C., Patassini S., Bari M., Gasperi V., De Ceballos M.L., Bernardi G., Maccarrone M., Cattaneo E., Fusco F.R. Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience 2008, 152:734-740.
10. De Petrocellis L., Cascio M.G., Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004, 141:765-774.
11. Essa M.M., Braidy N., Vijayan K.R., Subash S., Guillemin G.J. Excitotoxicity in the pathogenesis of autism. Neurotox Res 2013, 23:393-400.
12. García E., Limón D., Pérez-De La Cruz V., Giordano M., Díaz-Muñoz M., Maldonado P.D., Herrera-Mundo M.N., Pedraza-Chaverrí J., Santamaría A. Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine. Free Radic Res 2008, 42:892-902.
13. a ed.
14. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
15. Lauckner J.E., Hille B., Mackie K. The cannabinoid agonist WIN 55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A 2005, 102:19144-19149.
16. Lopachin R.M., Geohagen B.C., Gavin T. Synaptosomal toxicity and nucleophilic targets of 4-hydroxy-2-nonenal. Toxicol Sci 2009, 107:171-181.
17. Mehta A., Prabhakar M., Kumar P., Deshmukh R., Sharma P.L. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 2013, 698:6-18.
18. Palazuelos J., Aguado T., Pazos M.R., Julien B., Carrasco C., Resel E., Sagredo O., Benito C., Romero J., Azcoitia I., Fernández-Ruiz J., Guzmán M., Galve-Roperh I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009, 132:3152-3164.
19. Pérez-De La Cruz V., Königsberg M., Santamaría A. Kynurenine pathway and disease: an overview. CNS Neurol Dis Drug Targets 2007, 6:398-410.
20. Pérez-De La Cruz V., Königsberg M., Pedraza-Chaverri J., Herrera-Mundo N., Díaz-Muñoz M., Morán J., Fortoul-van der Goes T., Rondan-Zarate A., Maldonado P.D., Ali S.F., Santamaría A. Cytoplasmic calcium mediates oxidative damage in an excitotoxic/energetic deficit synergic model. Eur J Neurosci 2008, 27:1075-1085.
21. Pérez-De La Cruz V., Elinos-Calderón D., Carrillo-Mora P., Silva-Adaya D., Konigsberg M., Morán J., Ali S.F., Chánez-Cárdenas M.E., Pérez-De La Cruz G., Santamaría A. Time-course correlation of early toxic events in three models of striatal damage: modulation by proteases inhibition. Neurochem Int 2010, 56:834-842.
22. Pintor A., Tebano M.T., Martire A., Grieco R., Galluzzo M., Scattoni M.L., Pézzola A., Coccurello R., Felici F., Cuomo V., Piomelli D., Calamandrei G., Popoli P. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006, 51:1004-1012.
23. Pop E. Cannabinoids, endogenous ligands and synthetic analogs. Curr Opin Chem Biol 1999, 3:418-425.
24. Rami A., Ferger D., Krieglstein J. Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. Neurosci Res 1997, 27:93-97.
25. Rios C., Santamaría A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 1991, 16:1139-1143.
26. Robson P.J. Therapeutic potential of cannabinoid medicines. Drug Test Anal 2014, 6:24-30.
27. Rodríguez-Martínez E., Camacho A., Maldonado P.D., Pedraza-Chaverrí J., Santamaría D., Galván-Arzate S., Santamaría A. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res 2000, 858:436-439.
28. Sagredo O., Pazos M.R., Valdeolivas S., Fernández-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Patents CNS Drug Discov 2012, 7:41-48.
29. Sánchez-Blázquez P., Rodríguez-Muñóz M., Garzón J. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol 2014, 4:169.
30. Santamaría A., Galván-Arzate S., Lisý V., Ali S.F., Duhart H.M., Osorio-Rico L., Ríos C., St'astný F. Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 2001, 12:871-874.
31. Schönhofen P, de Medeiros LM, Bristot I,J, Lopes FM, De Bastiani MA, Kapczinski F, Crippa JAS, Castro MAA, Parsons RB, Klamt F (2014) Cannabidiol exposure during neuronal differentiation sensitizes cells against redox-active neurotoxins. Mol Neurobiol. http://dx.doi.org/10.1007/s12035-014-8843-1.
32. Schwarcz R., Guidetti P., Sathyasaikumar K.V., Muchowski P.J. Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol 2010, 90:230-245.
33. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012, 13:465-477.
34. Shirazi-Zand Z., Ahmad-Molaei L., Motamedi F., Naderi N. The role of potassium BK channels in anticonvulsant effect of cannabidiol in mice. Epilepsy Behavior 2013, 28:1-7. (pentylenetetrazole and maximal electroshock models of seizure in mice).
35. Silva V.S., Duarte A.I., Rego A.C., Oliveira C.R., Goncxalves P.P. Effect of chronic exposure to aluminium on isoform expression and activity of rat (Na+/K+)ATPase. Toxicol Sci 2005, 88:485-494.
36. Stone T.W., Mackay G.M., Forrest C.M., Clark C.J., Darlington L.G. Tryptophan metabolites and brain disorders. Clin Chem Lab Med 2003, 41:852-859.
37. Tavares R.G., Tasca C.I., Santos C.E., Wajner M., Souza D.O., Dutra-Filho C.S. Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. Neuroreport 2000, 11:249-253.
38. Vilela L.R., Medeiros D.C., Rezende G.H.S., P de Oliveira A.C., Moraes M.F.D., Moreira F.A. Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats. Epilepsy Res 2013, 104:195-202.
39. Zádori D., Klivényi P., Szalárdy L., Fülöp F., Toldi J., Vécsei L. Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders. J Neurol Sci 2012, 322:187-191.
40. Zhou C., Qi C., Zhao J., Wang F., Zhang W., Li C., Jing J., Kang X., Chai Z. Interleukin-1β inhibits voltage-gated sodium currents in a time- and dose-dependent manner in cortical neurons. Neurochem Res 2011, 36:1116-1123.